Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

As the transition from the Enhancing Oncology Model to the Oncology Care Model beckons, cancer programs will need to be proactive as they undergo certain operational changes.
Cancer and its treatment impact patients in many ways, beginning before a diagnosis and lasting long through survivorship, including one's sexual health. All of Me was created to bridge this communication gap between patients and providers.
The Centers for Medicare and Medicaid Services highlighted the vision of healthcare organizations and professionals for the coming year.
An interview with Kathi Mooney, PhD, RN, FAAN, about the Huntsman at Home model, including the development and implementation of Symptom Care at Home.
An Innovative Medical-Legal Partnership Read how this 2022 ACCC Innovator Award winner assists patients with estate planning like bedside wills, powers of attorney, and advance directives, as well as issues related to insurance, employment, housing, family, immigration, education, and more: accc-cancer.org/vcu-partnership. Then attend the ACCC 39th National Oncology Conference, Oct. …
This pilot study aimed to determine the efficacy of a community-based wellness program offered to patients outside of the clinical setting.
The past decade has seen a dramatic increase in the cost of healthcare in the United States, and as insurers pass an increasing portion of healthcare costs to patients, hospitals are left to bear the burden unpaid medical fees.
Rare Triple Negative Breast Cancer Alexandra Thomas, MD, FACP Williams Family Chair in Breast Oncology Atrium Wake Forest Baptist Health Disclosure of Conflicts of Interest •Sanofi– research support (to the institution) •Lilly, Genentech – Consulting •Beyond Spring Pharmaceuticals – DSMB •Johnson and Johnson, Gilead Science, Pfizer, Bristol Myers Squibb, Doximity …
Genitourinary Cancers Update Matthew Milowsky, MD, FASCO 9/9/22 Disclosure of Conflicts of Interest Matt Milowsky, MD, FASCO has the following financial relationships to disclose: • Stock and Other Ownership Interests – Pfizer, Merck, Gilead Sciences • Consulting or Advisory Role – Loxo/Lilly • Research Funding (institution)–Merck, Roche/Genentech, Bristol-Myers …
Multiple Myeloma Updates Nasreen Vohra, MD, FACS, FSSO Associate Professor Interim Chief, Division of Surgical Oncology Department of Surgery Brody School of Medicine Disclosure of Conflicts of Interest Nasreen Vohra, MD, FACS, FSSO has the following financial relationship to disclose: Advisory Board – Castle Biosciences Case – Plantar Foot Melanoma …
Chronic Lymphocytic Leukemia: Where Are We Now and Where Are We Going? Andrea Sitlinger, MD Assistant Professor of Medicine Hematologic Malignancies and Cellular Therapy Duke Cancer Institute Disclosure of Conflicts of Interest Andrea Sitlinger, MD has the following financial relationships to disclose: • Consultant – BeiGene, TG Therapeutics • Speaker – Innate Pharma …
Optimizing value in molecular testing North Carolina Oncology Association Annual Conference Jason D. Merker, MD, PhD Associate Professor, Pathology and Laboratory Medicine & Genetics Director, Molecular Oncology jason_merker@med.unc.edu September 10, 2022 Disclosure of Conflicts of Interest Jason D. Merker, MD, PhD has the following financial relationships to disclose: …
Updates in Thoracic Oncology Tom Stinchcombe, MD Professor of Medicine Duke Cancer Institute Disclosure of Conflicts of Interest Activity Company Advisory board or data monitoring committee EMD Serono, Novartis, Janssen Oncology, Turning Point Therapeutics, Sanofi/Aventis, GlaxoSmithKline, Genentech/Roche, Daiichi Sankyo/Astra Zeneca, Takeda Research Funding …
Metastatic Colon and Rectal Cancer Updates, ASCO 2022 Colorectal and Anal Cancer Justin Chau, MD Hematology, Oncology, and Blood & Marrow Transplantation University of Iowa Hospitals and Clinics Disclosures I have no disclosures to report. Permission was obtained from ASCO to use the following slides from its 2022 Annual Meeting in this presentation. What …
CHANGING MEDICINE. CHANGING LIVES.® Colorectal & Anal Cancer Saima Sharif, MD MS September 9, 2022 Celebrating 150 years of advancing medical research, education, and patient care to help people live longer, healthier lives Disclosure of Conflict of Interest Insert->Header and Footer->Type Customizable Name Saima Sharif, MD, MS has the following relationship to …
Upper GI Hepatobiliary/Pancreatic Cancers Naomi Fei, MD MS University of Iowa Holden Cancer Center 9/9/22 Disclosure of Conflicts of Interest Naomi Fei, MD MS, has no financial relationships to disclose. Outline • Sequential Chemotherapy: SEQUENCE • Targeting mutant KRAS in PDAC: KRYSTAL-1 • KRAS WT PDAC: NOTABLE • Available Trials at UIHC …
An in-person conference event, featuring educational and networking opportunities for the multidisciplinary cancer care team on how to implement innovation in care delivery. West Palm Beach, Fla. — Oncology professionals will convene October 12-14, 2022, in West Palm Beach, Fla., to learn from and network with their colleagues through an engaging and interactive three-day agenda at the ACCC 39th National …
ASCO 2022 Updates – Spotlight on Breast Cancer Sneha Phadke, DO MPH Clinical Associate Professor Breast Medical Oncologist University of Iowa Holden Comprehensive Cancer Center Disclosures • Research support from Astra-Zeneca, Pfizer, Roche, Laekna • Many of the slides are courtesy of clinicaloptions.com or were adapted from them, tailored to the objectives of this …
Lung Cancer Maggie Byrne, MD, MS Clinical Assistant Professor Holden Comprehensive Cancer Center, University of Iowa Maggie Byrne, MD, MS has no relevant financial relationships to disclose. Disclosure of Conflicts of Interest Metastatic NSCLC without targetable genomic alterations 1st line Abstract 9000, Pooled analysis of 12 randomized studies comparing IO vs …
CHANGING MEDICINE. CHANGING LIVES.® Multiple Myeloma Updates from ASCO 2022 Christopher Strouse MD September 9th, 2022 Holden Comprehensive Cancer Center Disclosures • Advisory board –Glaxo Smith Kline • We will discuss off label / investigational uses Holden Comprehensive Cancer Center Acknowledgements • Thank you to the abstract presenters for use of their …